|  |
| --- |
| **Supplemental Table 1. Association of FGF-23 tertiles with frailty overall, by HIV serostatus, and by race** |
|   | **2nd vs 1st tertile** | **3rd vs 1st tertile** |
| **Overall** | **Hazard ratio (95% CI)** | **P-value** | **Hazard ratio (95% CI)** | **P-value** |
| Age-, race-adjusted | 2.42 (0.85-6.86) | 0.098 | 3.25 (1.17-8.97) | 0.023 |
| + HIV and kidney function\* | 2.36 (0.82-6.73) | 0.109 | 3.01 (1.08-8.39) | 0.035 |
| + other frailty-associated factors† | 2.45 (0.84-7.13) | 0.101 | 2.91 (1.02-8.28) | 0.045 |
| Multiple imputation‡ | 2.60 (0.89-7.63) | 0.081 | 3.23 (1.13-9.24) | 0.029 |
| **Fully adjusted models by HIV serostatus** |
| **HIV-infected €** | 2.81 (0.65-12.18) | 0.168 | 4.57 (1.19-17.56) | 0.027 |
| **HIV-uninfected¶** | 3.15 (0.58-17.11) | 0.184 | 1.45 (0.23-8.96) | 0.690 |
| **Fully adjusted models by race**¥ |  |  |  |  |
| **Black** | 10.82 (1.19-98.49) | 0.035 | 12.79 (1.47-111.46) | 0.021 |
| **Non-black** | 1.42 (0.39-5.15) | 0.596 | 1.51 (0.41-5.60) | 0.537 |
| **Note:** P-interaction for FGF-23 and HIV serostatus = 0.41; p-interaction for FGF-23 and race = 0.254\* Kidney function assessments included eGFR and UPCR>200 mg/g† Additionally adjusted for pre-2001 cohort, BMI, HCV co-infection, hypertension, diabetes mellitus, dyslipidemia, and smoking‡ Fully adjusted model with missing covariates addressed with multiple imputation**€** Adjusted for age, race, eGFR, UPCR>200 mg/g, pre-2001 cohort, BMI, HCV serostatus, hypertension, diabetes mellitus, dyslipidemia, smoking, cumulative TDF use,cumulative HAART use and prior AIDS**¶** Adjusted for age, race, eGFR, UPCR>200 mg/g, pre-2001 cohort, BMI, hypertension, diabetes mellitus, dyslipidemia, and smoking¥Adjusted for HIV serostatus, age, eGFR, UPCR>200 mg/g, BMI, HCV serostatus, hypertension, diabetes mellitus, and smoking. Cohort and dyslipidemia were not adjusted because they correlated strongly with race.*Abbreviations:* eGFR, estimated glomerular filtration rate; UPCR, urine protein-to-creatinine ratio; BMI, body mass index; HCV, hepatitis C virus; TDF, tenofovir disoproxil fumarate; HAART, highly active antiretroviral therapy |